Renal Denervation Devices Patent Landscape Analysis Report 2026 Edition

Renal Denervation Devices Market Size, Growth Trends, and Industry Outlook

The market growth is driven by the arrival of reimbursed, FDA-approved catheter systems that give physicians a procedural option for patients whose blood pressure stays elevated on medication. Hypertension affects roughly 1.3 billion adults worldwide according to the World Health Organization, and fewer than one in five have it under control. Resistant hypertension is estimated to affect 10 to 15 percent of treated patients.

The growth rate is high because the base is small. Commercial sales began in earnest only after the November 2023 FDA approvals of the Symplicity Spyral and Paradise systems, so each newly reimbursed procedure adds a large percentage to a low starting value. The 2025 national coverage decision from the Centers for Medicare and Medicaid Services extended payment to eligible Medicare patients, which removes the main barrier to hospital adoption in the United States.

Sham-controlled trials such as SPYRAL HTN-ON MED and RADIANCE II showed average office systolic reductions of several mmHg beyond sham, and these results gave guideline bodies the evidence to endorse the procedure. Positive evidence led to wider operator training and more catheterisation laboratories offering treatment. A larger procedure volume in turn raises demand for next-generation catheters, planning software and patient selection tools, which sustains patent filing.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Renal Denervation Devices Patent Filing Trends and Innovation Activity

Patent filing in renal denervation devices began in the mid-2000s with radiofrequency catheters and expanded after the first sham-controlled trial readouts. Early families addressed electrode design and energy delivery. Later filings added ultrasound transducers, alcohol-based perivascular injection and procedural planning.

The field holds more than 3,000 patent families, with filing peaks in 2012 to 2014 and again in 2021 to 2024. The second peak followed the neutral and positive trial readouts and the move toward regulatory approval. Granted patents for 2025 are in the low hundreds, which reflects a more selective prosecution environment.

Rising hypertension prevalence and new Medicare coverage push developers to protect catheter designs and delivery methods before commercial volumes scale.

Scope of the Renal Denervation Devices Patent Landscape Analysis Report

The analysis covers patents on radiofrequency, ultrasound and alcohol-mediated catheter systems used to ablate renal sympathetic nerves. It includes electrode and transducer design, generators, delivery catheters, sheaths and balloon cooling features.

Patents on procedural planning, renal anatomy imaging, patient selection and response prediction are included, along with methods supporting sham-controlled trial design. The population of interest is adults with uncontrolled or resistant hypertension, together with comorbid cardiometabolic groups.

Assignees include medical device manufacturers, pharmaceutical groups with device subsidiaries, start-ups, universities and hospital research institutes. Patent offices covered include the United States Patent and Trademark Office, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office and the World Intellectual Property Organization.

Global Renal Denervation Devices Patent Landscape Analysis

Renal Denervation Devices Patent Filing Trend Analysis

Filings grew at an estimated annual rate of 9 to 11 percent over 2020 to 2024, led by multi-electrode radiofrequency designs, ultrasound refinements and alcohol-mediated delivery. Regulatory approvals in 2023 and strong trial evidence supported this pace.

Chinese applicants raised their share of new filings during the period, driven by domestic radiofrequency and balloon catheter programmes. Software and patient selection filings increased as developers sought to improve responder identification. Continuation filings by established assignees extended protection around approved platforms.

Leading Companies and Assignee Analysis in the Renal Denervation Devices Patent Landscape

Geographic Analysis of Renal Denervation Devices Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads in filing volume and in granted patents on commercial platforms, supported by the 2023 approvals and 2025 coverage decision. China ranks second, driven by domestic device developers and a large hypertensive population. Europe follows, with filings tied to CE-marked systems and clinical sites in Germany, the United Kingdom and France.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Renal Denervation Devices Technology Segmentation and Innovation Areas

The report segments patent activity into the following technology areas:

• Radiofrequency ablation catheters
• Ultrasound denervation systems
• Alcohol-mediated injection catheters
• Procedural planning and imaging tools
• Patient selection and response prediction

Among these, radiofrequency ablation catheters account for the largest share of patent families, reflecting the early start of the Symplicity programme and many follow-on electrode designs.

Competitive Landscape and Emerging Trends in the Renal Denervation Devices Market

Medtronic and Recor Medical lead the field with the two FDA-approved platforms, and their portfolios cover radiofrequency and ultrasound energy respectively. Boston Scientific and Abbott bring broad cardiovascular catheter portfolios, while Ablative Solutions focuses on perivascular alcohol delivery. Litigation between Medtronic and Recor Medical over catheter claims shows how closely held this intellectual property has become.

Companies are focusing on:

• Multi-electrode radiofrequency spiral catheters
• Balloon-cooled ultrasound transducers
• Perivascular alcohol injection needles
• Distal and branch vessel ablation methods
• Renal artery mapping and nerve location
• Responder prediction using blood pressure and imaging data
• Sham-controlled trial monitoring and endpoint methods

Emerging innovation themes include non-invasive and focused ultrasound denervation, renal nerve mapping to guide energy delivery, and biomarkers to predict blood pressure response. Developers also file on lower-cost single-use catheters for emerging markets and on combined use with antihypertensive drug regimens. Interest in treating atrial fibrillation and heart failure through sympathetic modulation adds new application claims.

Strategic Insights from the Renal Denervation Devices Patent Landscape

The competitive field combines two leading approved platforms, large cardiovascular device groups entering through acquisition, and start-ups pursuing differentiated energy sources. Medicare coverage in 2025 increases the commercial value of claims on approved systems. Assignees with ultrasound and alcohol-mediated portfolios hold distinct positions against the radiofrequency incumbent.

Technology segments, jurisdictions and assignee portfolios in this report support decisions across R&D, licensing and market entry. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Renal Denervation Devices Patent Landscape Analysis

Patent data was collected from the United States Patent and Trademark Office, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office and the World Intellectual Property Organization. Search queries combined keywords with Cooperative Patent Classification codes such as A61B 18, A61N 7 and A61M 25, along with A61B 2018 sub-classes for renal nerve ablation.

Results were screened manually for relevance to renal denervation devices and consolidated into patent families to remove duplicate filings across jurisdictions. Assignee names were normalised to account for subsidiaries and acquisitions. Legal status, filing year and jurisdiction were coded for each family.

The market side draws on regulatory filings, company disclosures, clinical trial registries and peer-reviewed literature. Figures for patent counts and shares are analyst estimates based on sampled database results.

Related Reports

Cardiac Arrhythmia Epidemiology Forecast

Laparoscopic Devices Market

Cardiac Amyloidosis Epidemiology Forecast